Literature DB >> 1850233

Comparison of neutralizing antigens of recent isolates of infections bursal disease virus.

S K Reddy1, A Silim.   

Abstract

Monoclonal antibodies (MAbs) to a local turkey isolate (QT-1) of infectious bursal disease virus (IBDV) were produced to identify the virus-specific neutralizing proteins. Radioimmunoprecipitation assays showed that all the MAbs were specific for major viral protein, VP2. Two of the MAbs neutralized the local turkey and chicken isolates along with a reference strain belonging to serotype 1 but not the reference strain of serotype 2. The reactivities of the neutralizing MAbs against two reference strains and some recent field strains of IBDV isolated in the province of Québec were studied by indirect enzyme-linked immunosorbent assay and virus neutralization tests. The variations in the reactivities of the MAbs observed suggest differences in the neutralizing epitopes of the different isolates. Competitive binding assay using the MAbs revealed the presence of a third epitope involved in the neutralization of IBDV belonging to serotype 1.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1850233     DOI： 10.1007/bf01310772

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  8 in total

1.  Peptide map comparison of the proteins of infectious bursal disease virus.

Authors:  P Dobos
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

2.  Differentiation of infectious bursal disease viruses directly from infected tissues with neutralizing monoclonal antibodies: evidence of a major antigenic shift in recent field isolates.

Authors:  D B Snyder; D P Lana; P K Savage; F S Yancey; S A Mengel; W W Marquardt
Journal:  Avian Dis       Date:  1988 Jul-Sep       Impact factor: 1.577

3.  Peroxidase-labeled antibody. A new method of conjugation.

Authors:  P K Nakane; A Kawaoi
Journal:  J Histochem Cytochem       Date:  1974-12       Impact factor: 2.479

4.  Nucleic acid and structural proteins of infectious bursal disease virus isolates belonging to serotypes I and II.

Authors:  D J Jackwood; Y M Saif; J H Hughes
Journal:  Avian Dis       Date:  1984 Oct-Dec       Impact factor: 1.577

5.  Group and strain-specific neutralization sites of infectious bursal disease virus defined with monoclonal antibodies.

Authors:  D B Snyder; D P Lana; B R Cho; W W Marquardt
Journal:  Avian Dis       Date:  1988 Jul-Sep       Impact factor: 1.577

6.  Isolation of infectious bursal disease virus from turkeys with arthritic and respiratory symptoms in commercial farms in Quebec.

Authors:  S K Reddy; A Silim
Journal:  Avian Dis       Date:  1991 Jan-Mar       Impact factor: 1.577

7.  The characterization and molecular cloning of the double-stranded RNA genome of an Australian strain of infectious bursal disease virus.

Authors:  A A Azad; S A Barrett; K J Fahey
Journal:  Virology       Date:  1985-05       Impact factor: 3.616

8.  Isolation and serological studies with infectious bursal disease viruses from fowl, turkeys and ducks: demonstration of a second serotype.

Authors:  J B McFerran; M S McNulty; E R McKillop; T J Connor; R M McCracken; D S Collins; G M Allan
Journal:  Avian Pathol       Date:  1980-07       Impact factor: 3.378
  8 in total
  11 in total

1.  Naturally occurring-neutralizing monoclonal antibody escape variants define the epidemiology of infectious bursal disease viruses in the United States.

Authors:  D B Snyder; V N Vakharia; P K Savage
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

Review 2.  Infectious bursal disease virus: a review of molecular basis for variations in antigenicity and virulence.

Authors:  M M Nagarajan; F S Kibenge
Journal:  Can J Vet Res       Date:  1997-04       Impact factor: 1.310

3.  Sequence conservation in the RNA polymerase gene of infectious bursal disease viruses.

Authors:  F S Kibenge; B Qian
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

4.  Hypericum perforatum extract therapy for chickens experimentally infected with infectious bursal disease virus and its influence on immunity.

Authors:  Ruofeng Shang; Cheng He; Jiongran Chen; Xiuying Pu; Yu Liu; Lanying Hua; Ling Wang; Jianping Liang
Journal:  Can J Vet Res       Date:  2012-07       Impact factor: 1.310

5.  Antigenic properties and diagnostic potential of baculovirus-expressed infectious bursal disease virus proteins VPX and VP3.

Authors:  J L Martínez-Torrecuadrada; B Lázaro; J F Rodriguez; J I Casal
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

6.  Selection of an infectious bursal disease virus mutant with increased immunogenicity following passage under humoral immune pressure.

Authors:  M M Nagarajan; F S Kibenge; A López
Journal:  Can J Vet Res       Date:  2001-04       Impact factor: 1.310

7.  A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV.

Authors:  Zhuhui Huang; Subbiah Elankumaran; Abdul S Yunus; Siba K Samal
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  Biological roles of the major capsid proteins and relationships between the two existing serotypes of infectious bursal disease virus.

Authors:  S K Reddy; A Silim; M J Ratcliffe
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

9.  Epitope mapping of capsid proteins VP2 and VP3 of infectious bursal disease virus.

Authors:  T Yamaguchi; K Iwata; M Kobayashi; M Ogawa; H Fukushi; K Hirai
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

10.  Evaluation of VP2 epitopes of infectious bursal disease virus using in vitro expression and radioimmunoprecipitation.

Authors:  J M Crisman; R J Jackwood; D P Lana; D J Jackwood
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.